PMC8716780_01
PMC8716780_02
PMC8716780_03
All 3 patients underwent multiple attempts at titrating their respective TKI therapies to the FDA label dosages but were limited by toxicities. Their titration timeline is as above. At 6 weeks, none of the patients would have met their corresponding minimum FDA label dosages of sorafenib 400mg QOD, regorafenib 80mg QD, or cabozantinib 20mg QD.
fonc-11-780798-g001.jpg
PMC8716780_03_fonc-11-780798-g001.jpg
f1
PMC8716780_04